RE:A must watch PMX presentation by Dr. Kellum Interesting video and Q&A that touched on some hot topics previously mentioned here, such as :
1. the interesting data subset of patients under Euphrates that experienced the highest benefit from PMX - namely those with no culturable bacteria but still endotoxemic. This subgroup would otherwise have no treatment. It seems that this will be studied over time ( shout out to STT for raising this many times )
2. benefits of hemoperfusion to Covid patients ( second speaker)
3. possible ( probable?) benefits to sicker patients ( eg those with higher EAA readings eg > .9 ) " we are not going to give up on those patients". Suggestions of altering dosage ( longer duration, more treatments, etc.)
BTW each one of these areas can and likely WILL result in SIGNIFICANT increases in revenue generated by PMX, and the EAA, if and or once PMX is finally approved.
MM